Switching to Bortezomib may Improve Recovery From Severe Vincristine Neuropathy in Pediatric Acute Lymphoblastic Leukemia

The purpose of this study was to evaluate the impact of switching patients being treated for acute lymphoblastic leukemia (ALL) from vincristine to bortezomib. A total of 20 patients with ALL were switched from vincristine to bortezomib (1.3 mg/m/dose) because of worsening neuropathy despite physica...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of pediatric hematology/oncology Vol. 41; no. 6; p. 457
Main Authors:	Joshi, Jaitri, Tanner, Lynn, Gilchrist, Laura, Bostrom, Bruce
Format:	Journal Article
Language:	English
Published:	United States 01.08.2019
Subjects:	Adolescent Adult Antineoplastic Agents - therapeutic use Antineoplastic Agents, Phytogenic - adverse effects Bortezomib - therapeutic use Child Child, Preschool Drug Substitution - statistics & numerical data Female Follow-Up Studies Humans Male Nervous System Diseases - chemically induced Nervous System Diseases - pathology Nervous System Diseases - prevention & control Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Prognosis Retrospective Studies Vincristine - adverse effects Young Adult
ISSN:	1536-3678, 1536-3678
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!